Evidence map›Paper›PMID 37709321›Full record

ArticleBMJ open2023

Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.

Suliana Teoh, Alexander Ooms, Ben George, Rob Owens, Kwun-Ye Chu, Joe Drabble, Maxwell Robinson, Matthew J Parkes, Lynda Swan, Lucinda Griffiths and 4 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Pancreatic Cancer and Diabetes: Insights, Hypotheses, and Next Steps.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Suliana TeohDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-5456-9273
Alexander OomsNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Disorders, University of Oxford, Oxford, UK.ORCID 0000-0003-1877-8323
Ben GeorgeDepartment of Stereotactic and MR-guided Radiotherapy, GenesisCare UK, Oxford, UK.
Rob OwensDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Kwun-Ye ChuDepartment of Oncology, University of Oxford, Oxford, UK.
Joe DrabbleDepartment of Stereotactic and MR-guided Radiotherapy, GenesisCare UK, Oxford, UK.
Maxwell RobinsonDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Matthew J ParkesOxford Clinical Trials Research Unit (OCTRU), Oxford University, Oxford, UK.ORCID 0000-0002-1574-9933
Lynda SwanDepartment of Oncology, University of Oxford, Oxford, UK.
Lucinda GriffithsDepartment of Oncology, University of Oxford, Oxford, UK.
Killian NugentDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0001-6225-9497
James GoodDepartment of Stereotactic and MR-guided Radiotherapy, GenesisCare UK, Oxford, UK.
Tim MaughanDepartment of Oncology, University of Oxford, Oxford, UK.
Somnath MukherjeeDepartment of Oncology, University of Oxford, Oxford, UK somnath.mukherjee@oncology.ox.ac.uk.
University of Oxford · GBOxford University Hospitals NHS Trust · GBNuffield Orthopaedic Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnline adaptive MR-guided radiotherapy allows for dose escalation to pancreatic cancer while sparing surrounding critical organs. We seek to evaluate the safety of delivering hypofractionated five-fraction, three-fraction and single-fraction MR-guided stereotactic ablative radiotherapy (SABR) to the pancreas. METHODS AND ANALYSIS: This is a single-centre three-arm phase 1 non-randomised safety study. Patients with localised pancreatic cancer will receive either 50 Gy in five (biological equivalent dose (BED ETHICS AND DISSEMINATION: The trial is approved by the West Midlands-Black Country Research Ethics Committee 22/WM/0122. The results will be disseminated via conference presentations, peer-reviewed scientific journals and submission to regulatory authorities. The data collected for the study, including individual participant data, will be made available to researchers on request to the study team and with appropriate reason, via octo-enquiries@oncology.ox.ac.uk. The shared data will be deidentified participant data and will be available for 3 years following publication of the study. Data will be shared with investigator support, after approval of a proposal and with a signed data access agreement. TRIAL REGISTRATION NUMBER: ISRCTN10557832.

Indexed as

Pancreatic NeoplasmsRadiation Dose HypofractionationBayes TheoremClinical Trials, Phase I as TopicHospitals, UniversityHumansPancreasUnited KingdomHepatobiliary tumoursMagnetic resonance imagingRadiation oncology

Identifiers

PMID37709321
PMCPMC10503372
OpenAlexW4386737819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.